Form 8-K · Current Report · Filed 2026-05-11
Moderna Updates By-Laws and Announces Annual Meeting Results
On May 6, 2026, Moderna, Inc. announced several key governance and shareholder actions. The Board of Directors approved an amendment to the company's by-laws to designate federal district courts as the exclusive forum for securities-related complaints. Additionally, at the 2026 Annual Meeting of Stockholders, directors were elected, executive compensation was approved on an advisory basis, and the appointment of Ernst & Young LLP as the independent auditor was ratified. The meeting also resulted in a decision to hold annual advisory votes on executive compensation.
- Filer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Accession
- 0001682852-26-000101
- CIK
- 0001682852
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$54.35
Next session
-2.0%
Since filing
+0.9%
Latest close
$54.82
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MRNA reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, MRNA insiders reported 59 Form 4 transactions — net selling of $4.6M.
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Never miss another MRNA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.